Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

URGN

UroGen Pharma Ltd

Jun 13 • 04:00PM ET

12.03

Dollar change +0.95
Percentage change 8.57	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT BIIB EXEL IONS FOLD ACAD NBIX VKTX PBYI HALO

| Held by: IWM IWO VTWO IZRL SPDW IBB IWC IWN SBIO ITEQ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.18	Insider Own	14.08%	Shs Outstand	46.10M	Perf Week	63.23%
Market Cap	554.67M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	-0.26%	Shs Float	39.62M	Perf Month	21.88%
Income	-138.43M	PEG	-	EPS next Q	-0.81	Inst Own	91.87%	Short Float	9.88%	Perf Quarter	8.67%
Sales	91.87M	P/S	6.04	EPS this Y	4.92%	Inst Trans	14.35%	Short Ratio	1.91	Perf Half Y	-0.08%
Book/sh	-1.01	P/B	-	EPS next Y	60.39%	ROA	-61.77%	Short Interest	3.92M	Perf Year	-8.10%
Cash/sh	4.27	P/C	2.82	EPS next 5Y	-	ROE	-	52W Range	3.42 - 20.70	Perf YTD	12.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.39%	ROIC	-176.37%	52W High	-41.88%	Beta	0.53
Dividend TTM	-	Quick Ratio	5.47	Sales past 5Y	449.77%	Gross Margin	89.68%	52W Low	251.75%	ATR (14)	1.44
Dividend Ex-Date	-	Current Ratio	5.65	EPS Y/Y TTM	6.32%	Oper. Margin	-117.51%	RSI (14)	71.89	Volatility	19.11% 20.45%
Employees	235	Debt/Eq	-	Sales Y/Y TTM	8.98%	Profit Margin	-150.68%	Recom	1.50	Target Price	35.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	4.41%	Payout	-	Rel Volume	9.43	Prev Close	11.08
Sales Surprise	-11.14%	EPS Surprise	-15.10%	Sales Q/Q	7.84%	Earnings	May 12 BMO	Avg Volume	2.05M	Price	12.03
SMA20	95.29%	SMA50	38.63%	SMA200	10.22%	Trades		Volume	19,322,104	Change	8.57%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-16-25	Initiated	Scotiabank	Sector Outperform	$23
Feb-19-25	Resumed	Ladenburg Thalmann	Buy	$31
Aug-22-24	Initiated	Guggenheim	Buy	$40
Feb-08-23	Downgrade	Jefferies	Buy → Hold	$35 → $10
Apr-27-22	Initiated	Berenberg	Buy	$20
Apr-16-20	Reiterated	H.C. Wainwright	Buy	$53 → $57
Apr-13-20	Reiterated	H.C. Wainwright	Buy	$75 → $53
Jan-09-20	Initiated	National Securities	Neutral	$37
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy	$82
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy	$50
Nov-15-17	Reiterated	Oppenheimer	Outperform	$32 → $51
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Jun-13-25 12:40PM	FDA approves UroGens Zusduri for non-muscle invasive bladder cancer (TipRanks) +8.57%
06:00AM	AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans (BioPharma Dive)
05:45AM	UroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGN (PR Newswire)
Jun-12-25 01:28PM	U.S. FDA Approves UroGens ZUSDURI (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire) +51.78%
Jun-06-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +43.39%
11:00AM	Loading…
Jun-02-25 11:00AM	UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer (Business Wire) +14.15%
10:00AM	UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
May-29-25 01:45PM	UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman (PR Newswire)
May-27-25 04:00PM	UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Business Wire) -6.21%
May-22-25 06:52AM	FDA advisers pan Pfizers PARP drug; Sarepta to resume Duchenne study (BioPharma Dive)
May-21-25 12:17PM	UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire) -44.69%
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.40%
May-13-25 03:05AM	UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... (GuruFocus.com) -8.98%
May-12-25 09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.32%
08:00AM	UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
10:32AM	Loading…
May-07-25 10:32AM	Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month (Seeking Alpha)
10:22AM	UroGen's bladder cancer treatment to be reviewed by FDA advisory committee (Seeking Alpha)
08:57AM	UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
May-01-25 04:00PM	UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (Business Wire)
Apr-29-25 05:16AM	Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Apr-27-25 04:00PM	OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment (Business Wire)
01:00PM	New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC (Business Wire)
12:30PM	New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC (Business Wire)
Apr-26-25 06:30PM	UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
10:00AM	UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer (Business Wire)
Apr-14-25 08:00AM	UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers (Business Wire)
Apr-12-25 10:02AM	UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy (Seeking Alpha)
Mar-12-25 03:00PM	UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
Mar-10-25 09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 (Business Wire)
08:00AM	Loading…
Mar-07-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 08:00AM	UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 (Business Wire)
Feb-25-25 12:30PM	Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
Feb-24-25 04:00PM	UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-21-25 10:53AM	UroGen acquires IconOVirs oncolytic virus assets (Pharmaceutical Technology) -5.88%
Feb-20-25 08:00AM	UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations (Business Wire)
Feb-14-25 02:30PM	UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 (Business Wire)
Feb-12-25 08:00AM	Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology (Business Wire)
Jan-30-25 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Jan-22-25 08:00AM	New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) (Business Wire)
Jan-15-25 08:00AM	ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 (Business Wire)
Dec-06-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-05-24 03:30PM	Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO (Business Wire)
03:15PM	UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC (Business Wire)
Dec-02-24 05:44PM	Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade (Zacks)
08:00AM	UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs (Business Wire)
Nov-28-24 11:49AM	UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment (Clinical Trials Arena)
Nov-26-24 08:00AM	New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO (Business Wire)
Nov-07-24 02:16AM	UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Nov-06-24 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 (Business Wire)
Nov-05-24 08:00AM	UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference (Business Wire)
Oct-30-24 08:00AM	UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 (Business Wire) +6.29%
Oct-28-24 08:00AM	ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC (Business Wire)
Oct-16-24 04:47AM	FDA accepts UroGens UGN-102 NDA for bladder cancer treatment (Pharmaceutical Technology)
Oct-15-24 04:30PM	UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 (Business Wire)
Oct-09-24 06:18PM	UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) -9.31%
08:00AM	UroGen Appoints Chris Degnan as Chief Financial Officer (Business Wire)
Oct-03-24 04:12AM	UroGen begins subject dosing in Phase III bladder cancer drug trial (Clinical Trials Arena)
Oct-02-24 08:00AM	First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Sep-23-24 05:50AM	UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now (Insider Monkey)
03:58AM	UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock (Insider Monkey)
Sep-16-24 08:00AM	UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041 (Business Wire)
Sep-05-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-24 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Aug-14-24 08:00AM	UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Aug-13-24 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights (Business Wire)
Aug-05-24 08:00AM	UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024 (Business Wire)
Aug-02-24 09:55AM	Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect? (Zacks)
Aug-01-24 10:01AM	Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-17-24 09:55AM	Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High? (Zacks)
Jun-27-24 01:54PM	UroGen Pharma Stock Earns 91 RS Rating (Investor's Business Daily)
Jun-17-24 10:51PM	UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants (Business Wire) -7.71%
04:46PM	UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
05:00AM	Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains? (Zacks)
Jun-13-24 04:05PM	UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug (Investor's Business Daily) +37.58% +9.71%
10:45AM	UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC (Business Wire)
Jun-07-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-24 08:00AM	UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024 (Business Wire)
Jun-05-24 08:00AM	UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (Business Wire)
Jun-03-24 08:00AM	UroGen Pharma Appoints David Lin as New Chief Commercial Officer (Business Wire)
May-22-24 08:00AM	UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit (Business Wire)
May-14-24 08:20AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-13-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:32AM	UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations (GuruFocus.com)
08:00AM	UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights (Business Wire)
May-07-24 08:00AM	UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
May-05-24 12:20PM	New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy (Business Wire)
May-04-24 03:20PM	UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 (Business Wire)
11:50AM	New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial (Business Wire)
May-03-24 08:00AM	UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024 (Business Wire)
Apr-17-24 12:02PM	UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers (Business Wire)
Apr-15-24 08:00AM	UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Apr-03-24 08:00AM	UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals (Business Wire)
Mar-15-24 10:30AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -17.97%
09:32AM	UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges (GuruFocus.com)
09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 (Business Wire)

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schoenberg Mark	Chief Medical Officer	Jun 09 '25	Sale	7.37	5,162	38,044	153,378	Jun 11 09:14 AM
Schoenberg Mark	Officer	Jun 09 '25	Proposed Sale	7.37	5,162	38,044		Jun 10 09:27 AM
Schoenberg Mark	Chief Medical Officer	Jan 31 '25	Sale	11.14	4,551	50,698	145,666	Feb 04 11:53 AM
Smith Jason Drew	General Counsel	Jan 31 '25	Sale	11.14	7,379	82,202	26,468	Feb 04 11:51 AM
Schoenberg Mark	Chief Medical Officer	Sep 09 '24	Sale	13.08	859	11,236	145,091	Sep 12 01:54 PM
Smith Jason Drew	General Counsel	Sep 09 '24	Sale	13.08	1,521	19,895	25,226	Sep 12 01:51 PM
Schoenberg Mark	Officer	Sep 09 '24	Proposed Sale	13.23	859	11,365		Sep 10 07:16 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

URGN

UroGen Pharma Ltd

Upgrade your FINVIZ experience